The Anti-inflammatory Effects of Inhaled Corticosteroids versus Anti-leukotrienes on the Lymphocyte P-Glycoprotein (PGP) Expression in Asthmatic Children
Authors:
- Frantisek KoprivaFKFrantisek Kopriva
- Petr DzubakPDPetr Dzubak
- Jan PotesilJPJan Potesil
- Marian HajduchMHMarian Hajduch
- 1 January 2009
- journal article
- research article
- Published by Taylor & Francis in Journal of Asthma
- Vol. 46 (4) , 366-370
Abstract
Inhaled corticosteroids (ICS) are used in asthma therapy for their anti-inflammatory effects. P-glycoprotein (PGP) is a transmembrane efflux pump for many drugs, including corticosteroids. Expression of PGP is associated with therapy resistant disease. The purpose of this study was to compare expression levels of PGP in blood lymphocytes of pediatric asthma patients either on ICS or on the leukotriene inhibitor montelukast medication. The evaluation of lymphocyte PGP expression was performed on a sample of 99 children (66 boys and 33 girls) aged 2-18 (median 12) years with intermittent or persisting mild asthma, (as defined by GINY 2002). The asthmatic children were divided into 3 groups: (1) treated by ICS budesonide 200-400 microg per day (n = 27) more than 1 year; (2) treated by oral montelukast 4 or 5 mg at an age-based dose (n = 16); and (3) treated by inhaled corticosteroids and montelukast (n = 45). Reference PGP values were obtained from a group of 64 healthy children (23 boys and 29 girls) aged 2-15 years (median, 10 years). The expression of lymphocyte PGP was determined on fixed and permeabilized blood mononuclear cells using indirect immunofluorescence staining technique by flow cytometry modified according to Boer et al., 1997. Based on the weighted medians for PGP expression in peripheral blood lymphocytes, we found a significant difference (p < 10(-3)) between the group of asthma patients (n = 99), (619 +/- 5.3) and healthy controls (n = 64) (446.9 +/- 4.4). Second, there was a lower level of PGP expression in the group treated by ICS (548.6 +/- 9) than the group treated by montelukast and montelukast with budesonide (643.2 +/- 6.3) (p < 10(-6)). The anti-inflammatory activity of ICS is more effective in decreasing the production of pro-inflammatory mediators and results in reduced multidrug resistence (MDR-1) gene activity and expression of lymphocyte PGP in asthmatic children.Keywords
This publication has 20 references indexed in Scilit:
- Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammationJournal of Allergy and Clinical Immunology, 2007
- ABCC10, ABCC11, and ABCC12Pflügers Archiv - European Journal of Physiology, 2006
- The power of the pump: Mechanisms of action of P-glycoprotein (ABCB1)European Journal of Pharmaceutical Sciences, 2006
- The effect of treatment with montelukast on in vitro interleukin‐10 production of mononuclear cells of children with asthmaClinical & Experimental Allergy, 2005
- Transport of Bile Acids, Sulfated Steroids, Estradiol 17-β-d-Glucuronide, and Leukotriene C4 by Human Multidrug Resistance Protein 8 (ABCC11)Molecular Pharmacology, 2005
- Function of the ABC Signature Sequences in the Human Multidrug Resistance Protein 1Molecular Pharmacology, 2004
- Constitutive Expression of P-Glycoprotein in Normal Lung Alveolar Epithelium and Functionality in Primary Alveolar Epithelial CulturesThe Journal of Pharmacology and Experimental Therapeutics, 2003
- From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significanceCellular and Molecular Life Sciences, 2001
- Identification, Molecular Cloning, Expression, and Characterization of a Cysteinyl Leukotriene ReceptorMolecular Pharmacology, 1999
- A Leukotriene Receptor Antagonist, ONO-1078, Modulates Drug Sensitivity and Leukotriene C4Efflux in Lung Cancer Cells Expressing Multidrug Resistance ProteinBiochemical and Biophysical Research Communications, 1998